002864.SHE Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
- Market cap
- CNY 2.73B
- P/E
- 41.7x
- P/B
- 1.56x
- ROE
- 4.4%
- Dividend yield
- 1.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002864.SHE undervalued?
Graham number002864.SHE trades 69.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A fundamental analysis
No fundamental analysis for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A yet.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Co., Ltd. researches and develops, produces, and sells Chinese patent medicines and traditional Chinese medicine formula granules in China. The company offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chinese medicine anti-inflammatory pr…
Full company profileShaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 305M | 377M | 489M | 611M | 670M | 887M | 974M | 981M | 974M | 1.14B | 824M |
| Gross Profit | 192M | 261M | 348M | 423M | 415M | 517M | 566M | 567M | 592M | 592M | 475M |
| Operating Income | 44.4M | 50.1M | 66.2M | 86.4M | 95.0M | 113M | 123M | 135M | 138M | 122M | 112M |
| EBITDA | 55.8M | 61.8M | 87.2M | 96.8M | 112M | 127M | 150M | 165M | 171M | 148M | 111M |
| Net Income | 39.5M | 43.7M | 64.7M | 71.8M | 79.1M | 93.2M | 101M | 110M | 120M | 96.3M | 75.4M |
| EPS | 0.61 | 0.65 | 0.75 | 0.83 | 0.92 | 1.09 | 1.17 | 1.13 | 1.15 | 0.70 | 0.55 |
| Balance Sheet | |||||||||||
| Total Assets | 504M | 753M | 818M | 929M | 1.16B | 1.33B | 1.93B | 2.13B | 2.28B | 2.32B | 2.28B |
| Total Liabilities | 177M | 197M | 206M | 254M | 427M | 523M | 983M | 574M | 643M | 634M | 575M |
| Shareholders' Equity | 328M | 556M | 612M | 675M | 721M | 791M | 930M | 1.55B | 1.64B | 1.69B | 1.70B |
| Cash & Short-term Investments | 126M | 301M | 85.1M | 168M | 382M | 419M | 823M | 1.10B | 1.17B | 1.09B | 1.16B |
| Total Debt | 20.0M | 3.00M | - | - | 107M | 144M | 427M | 102M | 151M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 62.0M | 28.4M | 46.8M | 67.9M | 92.2M | 116M | 125M | 104M | 157M | 63.0M | - |
| Capital Expenditure | 17.1M | 23.4M | 20.1M | 33.6M | 71.2M | 80.7M | 55.8M | 62.5M | 82.1M | 42.4M | 41.1M |
| Free Cash Flow | 44.9M | 5.00M | 26.8M | 34.3M | 21.1M | 35.4M | 69.5M | 41.5M | 74.5M | 20.6M | 279M |
| Ratios | |||||||||||
| ROE | 12.1% | 7.9% | 10.6% | 10.6% | 11.0% | 11.8% | 10.9% | 7.1% | 7.4% | 5.7% | 4.4% |
| ROA | 7.8% | 5.8% | 7.9% | 7.7% | 6.8% | 7.0% | 5.2% | 5.2% | 5.3% | 4.1% | 3.3% |
| Net Profit Margin | 12.9% | 11.6% | 13.2% | 11.8% | 11.8% | 10.5% | 10.4% | 11.3% | 12.3% | 8.4% | 9.2% |
| Debt to Equity | 0.06x | 0.01x | - | - | 0.15x | 0.18x | 0.46x | 0.07x | 0.09x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A dividends
- Dividend yield
- 1.61%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 45.6%
- Ex-dividend date
- Sep 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 43.9M | 0.32 | 45.6% |
| 2024 | CNY 24.5M | 0.23 | 20.4% |
| 2023 | CNY 24.3M | 0.25 | 22.0% |
| 2022 | CNY 21.1M | 0.24 | 20.8% |
| 2021 | CNY 17.9M | 0.21 | 19.2% |
| 2020 | CNY 13.0M | 0.15 | 16.4% |
| 2019 | CNY 8.67M | 0.10 | 12.1% |
| 2018 | CNY 8.67M | 0.10 | 13.4% |
| 2017 | CNY 359K | 0.01 | 0.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jul 22, 2026.
Who owns Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
- Insiders 40.99%
- Institutions 4.38%
- Public & others 54.63%
- Shares outstanding 137M
- Free float 86.1M
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A company profile
- Company name
- Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
- Ticker
- 002864.SHE
- ISIN
- CNE1000032C9
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 926
- Fiscal year end
- December
- Address
- No. 2801, Baliu 2nd Road, Xi'an, China, 710025
- Phone
- 86 29 8333 8888
- Website
- pljt.com
About Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Co., Ltd. researches and develops, produces, and sells Chinese patent medicines and traditional Chinese medicine formula granules in China. The company offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chinese medicine anti-inflammatory products. It also offers health food, health products, functional health food, and daily chemical products. The company was formerly known as Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd and changed its name to Shaanxi Panlong Pharmaceutical Group Co., Ltd. in May 2026. Shaanxi Panlong Pharmaceutical Group Co., Ltd. was founded in 1997 and is headquartered in Xi'an, China.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A management
7- Mr. Dezhu ZhangPresident, VP & Director · born 1976
- Mr. Fengming ZhuChief Financial Officer · born 1971
- Mr. Zhong MengVice President & Director · born 1983
- Mr. Jilin HuangVP & Director · born 1983
- Qian ChengAccounting Supervisor
- Mr. Qingshui LuoDirector of Legal Department · born 1961
- Ms. Qing Bo ZhaoBoard Secretary · born 1987